BCMA-directed therapy for early relapsed and/or refractory multiple myeloma

Competing interests

N.W.C.J.v.d.D. has received research support via his institution from Amgen, Bristol Myers Squibb (BMS), Celgene, Cellectis, Janssen and Novartis, and serves on advisory boards for AbbVie, Adaptive Biotech, Amgen, Bayer, BMS, Celgene, Janssen, Kite Pharma, Merck, Novartis, Pfizer, Roche, Sanofi, Servier and Takeda. S.Z. has received research support via her institution from Janssen and Takeda, and serves on advisory boards for BMS, GSK, Janssen, Oncopeptides, Sanofi and Takeda.

Comments (0)

No login
gif